Reporter brief
Assessing the Role of GLP-1 Receptor Agonist Semaglutide and Dual GLP-I/GIP Receptor Agonist Tirzepatide in Delaying Genetic Aging in Adult Obese Patients Using the iWatchAge Technology
What happened
Trial registry update: RECRUITING. No results reported in the supplied registry record.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- The abstract does not report any results, so it is unclear whether either GLP-1 agonist affected epigenetic aging or related biomarkers.
- The open-label design means participants and clinicians knew which treatment was given, creating potential for bias in subjective measures.
- The 24-week study period may be insufficient to detect meaningful changes in epigenetic aging, and comparison to metformin rather than placebo limits interpretation of drug-specific effects.
Study design and sample
Rct; Human.
Adults with simple obesity who have not used weight-loss medications for at least 3 months
- Design
- Rct
- Sample
- 66
- Journal
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Published
- Dec 19, 2025
Effect size
Not recorded.
Caveats
- Assessment: Unassessed.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the GLP-1 agonists timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.